Prognostic value of pretreatment 18f-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy

International Journal of Gynecological Cancer

Volumn 23, Issue 6, 2013, Pages 1104-1110

  Onal, Cem ^a   Reyhan, Mehmet ^a   Parlak, Cem ^a   Guler, Ozan Cem ^a   Oymak, Ezgi ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b SAKARYA UNIVERSITY   (Turkey)

Author keywords

Cervical cancer; Metabolic response; Positron emission tomography; Radiotherapy

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84880263393     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182989483     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Atahan IL, Onal C, Ozyar E, et al. Long-term outcome and prognostic factors in patients with cervical carcinoma: A retrospective study. Int J Gynecol Cancer. 2007;17:833-842.
3. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872-880.
4. Sommers GM, Grigsby PW, Perez CA, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol. 1989;35:150-155.
5. Haie-Meder C, Mazeron R, Magne N. Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol. 2010;96:351-355.
6. Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: Relationship to prognosis. J Clin Oncol. 2010;28:2108-2113.
7. Prudencio M, Jansen-West KR, Lee WC, et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci U S A. 2012;109:21510-21515.
8. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
9. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of nonYsmall-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
10. Xue F, Lin LL, Dehdashti F, et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 2006;101:147-151.
11. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26:1459-1464.
12. Schwarz JK, Siegel BA, Dehdashti F, et al. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298: 2289-2295.
13. Schwarz JK, Siegel BA, Dehdashti F, et al. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2012;83:185-190.
14. Kidd EA, Siegel BA, Dehdashti F, et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738-1744.
15. Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome. J Clin Oncol. 2004;22:2167-2171.
16. Onal C, Arslan G, Topkan E, et al. Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: Target volume coverage and organs at risk doses. J Exp Clin Cancer Res. 2009;28:95.
17. Onal C, Oymak E, Findikcioglu A, et al. Isolated mediastinal lymph node false positivity of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical cancer. Int J Gynecol Cancer. 2013;23:337-342.
18. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25: 571-578.
19. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353-359.
20. Chung HH, Kim JW, Han KH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270-274.
21. Beriwal S, Kannan N, Sukumvanich P, et al. Complete metabolic response after definitive radiation therapy for cervical cancer: Patterns and factors predicting for recurrence. Gynecol Oncol. 2012;127:303-306.
22. Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer. 2011;117:3981-3988.
23. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG PET. Radiology. 2001;218:776-782.
24. Lee YY, Choi CH, Kim CJ, et al. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary results. Gynecol Oncol. 2009;115:65-68.
25. Tong SY, Lee JM, Ki KD, et al. Correlation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancer. Int J Gynecol Cancer. 2012;22:654-658.
26. Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22-29.
27. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083-2095.